阿尔茨海默病及相关病2026，Vol.9Issue(3)：150-157,172,9.DOI:10.3969/j.issn.2096-5516.2026.03.002
尿液β-淀粉样蛋白检测试剂盒筛查认知下降风险在中国多家医院和社区的真实世界应用表现
Real-world performance of urine β-amyloid test kit in multiple hospital clinics and neighborhood communities of China
乔立艳 1脱厚珍 2王诗雅 2向光红 3周妮娜 3林勇 4王军 5王虹峥 6王桂红 7陈小童 8王静 1黄微 9邢冬梅 9赵庆芳 9王运良 10尹红蕾10
作者信息
- 1. 清华大学玉泉医院,北京 100049
- 2. 首都医科大学附属北京友谊医院,北京 100050
- 3. 湖南省第二人民医院,湖南 长沙 410007
- 4. 上海市静安区中心医院,上海 200040||国家老年疾病临床医学研究中心(华山),上海 200032
- 5. 北京交通大学生命科学与生物工程研究院,北京 100044
- 6. 北京协和医学院,北京 100006
- 7. 首都医科大学附属北京天坛医院,北京 100070
- 8. 上海市静安区中心医院,上海 200040
- 9. 云南省第三人民医院,云南 昆明 650011
- 10. 中国融通医疗健康集团淄博一四八医院,山东 淄博 255300
- 折叠
摘要
Abstract
Objective:To explore the real-world application performance of the urine β-amyloid protein detection kit in screening the risk of cognitive decline in multiple hospitals and communities in China.Methods:In this study,the clinical values of One-Step Dementia Risk Test Kit in early screening were further validated by community health screening in Changsha(n=51 187)and a multi-center,case-control study with a total of 898 participants including 266 healthy age-matched controls,167 MCI/AD patients and 465 non-AD patients with various comorbidities and age-related diseases.Results:The number of weak positive/positive/negative in the healthy,non-AD and MCI/AD group was 8/12/246(positivity 7.52%),41/16/409(12.23%)and 77/44/46(72.46%),respectively,resulting in a Kappa value of 0.669 which indicated a good diagnostic performance.Comorbidity analysis identified memory decline as the most significant risk factor(P=9.6×10-23,Fisher's Exact Test),followed by hyperlipidemia(P=3.2×10-12),history of stroke(P=0.0011)and hypertension(P=0.00058).Therapeutics analysis showed medications for cardiovascular diseases and anti-thrombosis significantly reduced risk of dementia(P=0.0061 and 0.0081,respectively).For AD patients,only patients receiving memantine treatment showed a slight reduction in kit positivity(P=0.0532).The kit also showed a clear age-dependent increase of positivity from 6.29%-15.40%,in health screening.Conclusions:Our results confirmed the diagnostic value of the kit in MCI and AD-dementia.Moreover,the kit can be used in the real world to assess the risk of various conditions towards AD as well as the treatment efficacy.关键词
尿液β-淀粉样蛋白/试剂盒/认知/早筛/共生病Key words
Urine β-amyloid/Kit/Cognition/Early screen/Comorbidity分类
医药卫生引用本文复制引用
乔立艳,脱厚珍,王诗雅,向光红,周妮娜,林勇,王军,王虹峥,王桂红,陈小童,王静,黄微,邢冬梅,赵庆芳,王运良,尹红蕾..尿液β-淀粉样蛋白检测试剂盒筛查认知下降风险在中国多家医院和社区的真实世界应用表现[J].阿尔茨海默病及相关病,2026,9(3):150-157,172,9.
